Pharsight

Morphabond Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(4 years from now)

US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making
Aug, 2028

(4 years from now)

Morphabond Er is owned by Daiichi Sankyo Inc.

Morphabond Er contains Morphine Sulfate.

Morphabond Er has a total of 2 drug patents out of which 0 drug patents have expired.

Morphabond Er was authorised for market use on 02 October, 2015.

Morphabond Er is available in tablet, extended release;oral dosage forms.

The generics of Morphabond Er are possible to be released after 12 August, 2028.

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MORPHABOND ER before it's drug patent expiration?
More Information on Dosage

MORPHABOND ER family patents

Family Patents